基于玉米醇溶蛋白-透明质酸载体的结肠靶向口服纳米药物研究  

Study on Colon-targeted Oral Nanomedicine Based on Zein-HA Carrier

作　　者：朱曙霞 王美玲 许紫宁 庾远龙 潘建林[1] 汪红娣 ZHU Shuxia;WANG Meiling;XU Zining;YU Yuanlong;PAN Jianlin;WANG Hongdi(College of Material,Chemistry and Chemical Engineering,Hangzhou Normal University,Hangzhou 311121,China)

机构地区：[1]杭州师范大学材料与化学化工学院,浙江杭州311121

出　　处：《杭州师范大学学报（自然科学版）》2024年第2期113-123,共11页Journal of Hangzhou Normal University(Natural Science Edition)

基　　金：浙江省自然科学基金项目(LQ20B060003);杭州师范大学科研启动经费项目(2018QDL040).

摘　　要：设计基于玉米醇溶蛋白(Zein)-透明质酸(HA)的口服纳米载体用于结肠靶向的药物递送.使用超声透析法制备玉米醇溶蛋白-透明质酸-羟基喜树碱(HCPT)纳米药物(Zein-HA@HCPT),利用渴望函数分析法优化纳米药物制备条件,考察纳米药物的微结构、药物释放行为、细胞毒性和靶向摄取能力.Zein-HA@HCPT具有95%以上的药物包封率,有优异的生物学稳定性、生物相容性和独特的抗胃酸分解特性,结肠环境下的药物累积释放显著提升.Zein-HA@HCPT通过CD44受体介导的内吞作用被结肠癌细胞靶向摄取,可提高药物抗肿瘤疗效.Oral nanocarriers for colon-targeted medicine delivery based on Zein-hyaluronic acid(HA)were designed in this study.The nanomedicine of Zein-HA-hydroxycamptothecin(Zein-HA@HCPT)was prepared by the ultrasound dialysis method.The preparation conditions of the nanomedicine were optimized by desirability function.The microstructure,drug release behavior,cytotoxicity and targeted cellular uptake ability of the nanomedicine were investigated.The results showed that Zein-HA@HCPT possessed a high drug encapsulation efficiency over 95%.Meantime,it exhibited excellent biological stability,biocompatibility,and unique gastric acid resistance.The cumulative release of drugs in the colonic environment was significantly improved.Furthermore,Zein-HA@HCPT was targeted and taken up by colon cancer cells through CD44 receptor mediated endocytosis,which can improve the anti-tumor efficacy of drugs.

关 键 词：玉米醇溶蛋白 透明质酸 羟基喜树碱 结肠靶向 

分 类 号：TQ46[化学工程—制药化工]